Phaseline

Companies › Kali Therapeutics

Kali Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Immunology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KT501
Monoclonal antibody targeting CD19, BCMA and CD3 to deplete B cells and plasma cells
CD19, BCMA, CD3Phase 1Rheumatoid Arthritis (RA)Feb 2027
KT502
Monoclonal antibody targeting CD19 and CD3 for B cell depletion
CD19, CD3Phase 1Rheumatoid Arthritis (RA)Dec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07234773KT501Phase 1Rheumatoid Arthritis (RA)ImmunologyFeb 2027
NCT07564154KT502Phase 1Rheumatoid Arthritis (RA)ImmunologyDec 2027

Targets

CD19 (2) CD3 (2) BCMA (1)

Companies with the same targets

Chongqing Precision Biotech Gilead Sciences Bristol-Myers Squibb AstraZeneca iCell Gene Therapeutics Excyte Biopharma Allogene Therapeutics Vironexis Biotherapeutics Miltenyi Biomedicine Roche

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.